{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.9","upperLimit":"93.4","value":"86.6"},{"groupId":"OG001","lowerLimit":"64.3","upperLimit":"87.4","value":"78.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"To compare the overall survival (OS) of patients treated with the consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine.\n\nOS event = Registration/Randomization to Death due to any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.\n\n\\>\n\n\\> carmustine: Given IV\n\n\\>\n\n\\> thiotepa: Given IV\n\n\\>\n\n\\> stem cell transplant\n\n\\>\n\n\\> G-CSF","id":"OG000","title":"Arm I"},{"description":"Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.\n\n\\>\n\n\\> cytarabine: Given IV\n\n\\>\n\n\\> etoposide: Given IV\n\n\\>\n\n\\> G-CSF","id":"OG001","title":"Arm II"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants alive"}